TY  - JOUR

T1  - CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply

JO  - The Lancet Oncology

UR  - https://eprints.whiterose.ac.uk/182549/

PY  - 2022/01/01

AU  - Fennell DA

AU  - Griffiths G

AU  - Ottensmeier C

AU  - Hanna GG

AU  - Danson S

AU  - Szlosarek P

AU  - Nye M

ED  - 

DO  - DOI: 10.1016/S1470-2045(21)00722-1

PB  - Elsevier

VL  - 23

IS  - 1

SP  - e14

EP  - e15

Y2  - 2024/09/19

ER  -